Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-83M | $-46M | $-62M | -56.3% | - | 26.1% |
| 2024 | $0M | $-70M | $-36M | $-47M | -57.9% | - | -69.0% |
| 2023 | $0M | $-43M | $-117M | $-40M | 240.4% | - | 32.5% |
| 2022 | $0M | $-39M | $-88M | $-28M | -104.5% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 39.78 | 43 | 70.58 | 83.25 |
| Research And Development | - | 27.08 | 30.31 | 51.96 | 66.27 |
| Selling General And Administration | - | 12.70 | 12.69 | 18.61 | 16.98 |
| Total Expenses | - | 39.78 | 43 | 70.58 | 83.25 |
| Operating Income | - | -39.78 | -43 | -70.58 | -83.25 |
| Total Operating Income As Reported | -36.87 | -88.43 | -43 | - | - |
| EBITDA | - | -39.41 | -42.63 | -70.22 | -82.94 |
| Normalized EBITDA | - | 9.24 | 33.58 | -101.12 | -116.39 |
| EBIT | - | -39.78 | -43 | -70.58 | -83.25 |
| Net Interest Income | 0 | - | - | - | - |
| Other Non Operating Income Expenses | - | 0.46 | 2.67 | 3.92 | 4.22 |
| Other Income Expense | - | -48.19 | -73.54 | 34.82 | 37.67 |
| Net Non Operating Interest Income Expense | 0 | - | - | - | - |
| Pretax Income | - | -87.97 | -116.54 | -35.75 | -45.58 |
| Tax Provision | - | 0 | 0 | 0.43 | 0.04 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 6.49 | 7.02 |
| Net Income Continuous Operations | - | -87.97 | -116.54 | -36.18 | -45.62 |
| Net Income From Continuing And Discontinued Operation | - | -87.97 | -116.54 | -36.18 | -45.62 |
| Net Income From Continuing Operation Net Minority Interest | - | -87.97 | -116.54 | -36.18 | -45.62 |
| Net Income | - | -87.97 | -116.54 | -36.18 | -45.62 |
| Net Income Common Stockholders | - | -87.97 | -116.54 | -36.18 | -45.62 |
| Net Income Including Noncontrolling Interests | - | -87.97 | -116.54 | -36.18 | -45.62 |
| Normalized Income | - | -39.32 | -40.33 | -60.60 | -72.04 |
| Diluted NI Availto Com Stockholders | - | -87.97 | -116.54 | -36.18 | -45.62 |
| Basic Average Shares | - | 14.29 | 24.62 | 48.54 | 81.84 |
| Diluted Average Shares | - | 14.29 | 24.62 | 48.54 | 81.84 |
| Reconciled Depreciation | - | 0.37 | 0.37 | 0.36 | 0.31 |
| Total Unusual Items | - | -48.65 | -76.21 | 30.90 | 33.45 |
| Total Unusual Items Excluding Goodwill | - | -48.65 | -76.21 | 30.90 | 33.45 |
| Special Income Charges | 0 | -48.65 | 0 | - | - |
| Impairment Of Capital Assets | 0 | 48.65 | 0 | - | - |
| Restructuring And Mergern Acquisition | 0 | - | - | - | - |
| Gain On Sale Of Security | - | - | -76.21 | 30.90 | 33.45 |
| General And Administrative Expense | - | 12.70 | 12.69 | 18.61 | 16.98 |
| Other Gand A | - | 12.70 | 12.69 | 6.35 | 7.24 |
| Salaries And Wages | - | - | - | 12.26 | 9.74 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc.this co. | ELDN | $278M | -6.09 | 3.43 | -56.3% | -3.08 |
| Alpha Teknova, Inc. | TKNO | $291M | -16.87 | 4.23 | -25.1% | -30.89 |
| OraSure Technologies, Inc. | OSUR | $287M | -4.18 | 0.84 | -20.2% | -1.74 |
| Niagen Bioscience, Inc. | NAGE | $279M | 16.04 | 3.64 | 22.7% | 13.78 |
| Quantum-Si incorporated | QSI |
| - |
| - |
| - |
| - |
| - |
| $279M |
| -2.75 |
| 1.27 |
| -46.0% |
| -2.81 |
| Entrada Therapeutics, Inc. | TRDA | $272M | -1.89 | 0.89 | -47.0% | -1.51 |
| Anavex Life Sciences Corp. | AVXL | $261M | -5.63 | 2.75 | -48.9% | - |
| Akebia Therapeutics, Inc. | AKBA | $260M | -48.70 | 7.98 | -16.4% | 5.86 |
| Fate Therapeutics, Inc. | FATE | $258M | -1.89 | 1.24 | -65.8% | -2.14 |
| Peer Median | - | -3.46 | 2.01 | -35.6% | -1.74 | |
Historically, Oct has averaged the highest return (+27.1%); Nov the lowest (-17.9%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +45.7%Positive MonthJan 2026: +45.70% | +19.1%Positive MonthFeb 2026: +19.09% | +17.6%Positive MonthMar 2026: +17.56% | +18.2%Positive MonthApr 2026: +18.18% | +4.7%Positive MonthMay 2026: +4.67% | +3.4%Positive MonthJun 2026: +3.41% | -14.2%Negative MonthJul 2026: -14.21% | +5.0%*Positive MonthAug 2026: +5.03% | — | — | — | — |
| 2025 | +9.7%Positive MonthJan 2025: +9.71% | -8.2%Negative MonthFeb 2025: -8.19% | -18.3%Negative MonthMar 2025: -18.31% | -6.8%Negative MonthApr 2025: -6.78% | -5.1%Negative MonthMay 2025: -5.06% | -9.7%Negative MonthJun 2025: -9.67% | +16.2%Positive MonthJul 2025: +16.24% | -17.8%Negative MonthAug 2025: -17.78% | +0.0%Neutral MonthSep 2025: +0.00% | +66.8%Positive MonthOct 2025: +66.80% | -62.3%Negative MonthNov 2025: -62.27% | -7.4%Negative MonthDec 2025: -7.36% |
| 2024 | -1.1%Neutral MonthJan 2024: -1.11% | +1.1%Neutral MonthFeb 2024: +1.12% | +14.4%Positive MonthMar 2024: +14.44% | +16.0%Positive MonthApr 2024: +16.02% | +15.1%Positive MonthMay 2024: +15.06% | -4.0%Negative MonthJun 2024: -4.00% | +11.4%Positive MonthJul 2024: +11.36% | -4.4%Negative MonthAug 2024: -4.42% | -11.4%Negative MonthSep 2024: -11.39% | +86.7%Positive MonthOct 2024: +86.75% | +0.2%Neutral MonthNov 2024: +0.22% | -11.6%Negative MonthDec 2024: -11.59% |
| 2023 | +45.6%Positive MonthJan 2023: +45.61% | -28.9%Negative MonthFeb 2023: -28.92% | +0.0%Neutral MonthMar 2023: +0.00% | -11.0%Negative MonthApr 2023: -11.02% | +0.0%Neutral MonthMay 2023: +0.00% | -34.8%Negative MonthJun 2023: -34.76% | +0.7%Neutral MonthJul 2023: +0.73% | +10.1%Positive MonthAug 2023: +10.14% | -9.9%Negative MonthSep 2023: -9.87% | +13.9%Positive MonthOct 2023: +13.87% | -26.3%Negative MonthNov 2023: -26.28% | +56.5%Positive MonthDec 2023: +56.52% |
| 2022 | -8.2%Negative MonthJan 2022: -8.16% | -12.8%Negative MonthFeb 2022: -12.84% | +11.6%Positive MonthMar 2022: +11.61% | -22.3%Negative MonthApr 2022: -22.34% | +4.2%Positive MonthMay 2022: +4.25% | -23.5%Negative MonthJun 2022: -23.51% | +23.4%Positive MonthJul 2022: +23.36% | +24.6%Positive MonthAug 2022: +24.58% | -26.4%Negative MonthSep 2022: -26.40% | -12.7%Negative MonthOct 2022: -12.68% | +1.2%Neutral MonthNov 2022: +1.24% | -6.6%Negative MonthDec 2022: -6.56% |
| 2021 | — | — | — | — | -4.8%Negative MonthMay 2021: -4.80% | -16.9%Negative MonthJun 2021: -16.91% | -18.0%Negative MonthJul 2021: -17.95% | +28.2%Positive MonthAug 2021: +28.20% | -25.7%Negative MonthSep 2021: -25.72% | -19.1%Negative MonthOct 2021: -19.09% | -2.2%Negative MonthNov 2021: -2.20% | -9.8%Negative MonthDec 2021: -9.82% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
